CN107531752B - 用于炎症和纤维化的肽治疗 - Google Patents

用于炎症和纤维化的肽治疗 Download PDF

Info

Publication number
CN107531752B
CN107531752B CN201680024300.0A CN201680024300A CN107531752B CN 107531752 B CN107531752 B CN 107531752B CN 201680024300 A CN201680024300 A CN 201680024300A CN 107531752 B CN107531752 B CN 107531752B
Authority
CN
China
Prior art keywords
ebp
lys
peptide
asp
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680024300.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107531752A (zh
Inventor
M·赛基亚
M·巴克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to CN202210439797.XA priority Critical patent/CN114621318A/zh
Priority to CN202111595612.6A priority patent/CN114181281A/zh
Publication of CN107531752A publication Critical patent/CN107531752A/zh
Application granted granted Critical
Publication of CN107531752B publication Critical patent/CN107531752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201680024300.0A 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗 Active CN107531752B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210439797.XA CN114621318A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202111595612.6A CN114181281A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160173P 2015-05-12 2015-05-12
US62/160,173 2015-05-12
PCT/US2016/026966 WO2016182660A1 (en) 2015-05-12 2016-04-11 Peptide treatment for inflammation and fibrosis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202111595612.6A Division CN114181281A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202210439797.XA Division CN114621318A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Publications (2)

Publication Number Publication Date
CN107531752A CN107531752A (zh) 2018-01-02
CN107531752B true CN107531752B (zh) 2022-05-10

Family

ID=57248348

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680024300.0A Active CN107531752B (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202210439797.XA Pending CN114621318A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202111595612.6A Pending CN114181281A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210439797.XA Pending CN114621318A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202111595612.6A Pending CN114181281A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Country Status (7)

Country Link
US (1) US10434134B2 (https=)
EP (1) EP3294752B1 (https=)
JP (1) JP7372026B2 (https=)
CN (3) CN107531752B (https=)
AU (1) AU2016260190A1 (https=)
CA (1) CA2984769C (https=)
WO (1) WO2016182660A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531752B (zh) * 2015-05-12 2022-05-10 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3562506A4 (en) * 2016-12-29 2021-01-06 University of Miami METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
WO2020010273A1 (en) 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
CN113301914B (zh) * 2018-10-25 2026-02-03 尼希尔有限公司 用于治疗和预防纤维化的组合物和方法
CN111770539B (zh) * 2019-04-02 2021-07-09 大唐移动通信设备有限公司 一种lmf选择方法、终端定位服务方法及装置
US20220411500A1 (en) * 2019-11-18 2022-12-29 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
CN114134191B (zh) * 2020-09-04 2023-12-12 琛蓝(美国)营养制品股份有限公司 一种抗炎护肾的蛤蜊肽的制备方法和应用
CN112960780B (zh) * 2021-03-03 2023-02-03 龙江环保集团股份有限公司 一种生物膜载体的预处理方法及生物法污水处理工艺
DE102022203153A1 (de) 2022-03-31 2023-10-05 Psa Automobiles Sa Stauraumanordnung für einen Innenraum eines Fahrzeugs, Fahrzeug mit der Stauraumanordnung und Verfahren zur Benutzung einer Stauraumanordnung
KR102772405B1 (ko) * 2022-06-10 2025-02-26 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도
CN115850440B (zh) * 2022-12-09 2023-07-11 中国人民解放军陆军军医大学 一种长链MyD88诱饵肽及其作为药物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678336A (zh) * 2002-02-21 2005-10-05 加州大学校务委员会 用细胞凋亡诱导方法治疗疾病
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
WO2010014830A2 (en) * 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129349B2 (en) 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
AU2002241776A1 (en) * 2000-10-27 2002-06-18 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7119071B2 (en) * 2002-05-21 2006-10-10 University Of Medicine And Dentistry Of New Jersey Amino terminal substance P compositions and methods for using the same
KR20080007491A (ko) * 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
US8865657B2 (en) * 2005-08-19 2014-10-21 New York University Compositions and methods for inactivating or suppressing inflammatory cells
EP2734220A4 (en) * 2011-07-19 2015-01-21 Thrasos Innovation Inc ANTIFIBROTIC PEPTIDES AND THEIR USE IN METHODS OF TREATING FIBROSIS-CHARACTERIZED DISEASES AND SUFFERING
CN108310396B (zh) * 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
CN107531752B (zh) * 2015-05-12 2022-05-10 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678336A (zh) * 2002-02-21 2005-10-05 加州大学校务委员会 用细胞凋亡诱导方法治疗疾病
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
WO2010014830A2 (en) * 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof

Also Published As

Publication number Publication date
CA2984769A1 (en) 2016-11-17
CN114621318A (zh) 2022-06-14
CN114181281A (zh) 2022-03-15
US20180125919A1 (en) 2018-05-10
AU2016260190A1 (en) 2017-11-23
EP3294752B1 (en) 2020-11-04
CN107531752A (zh) 2018-01-02
NZ736840A (en) 2024-05-31
EP3294752A4 (en) 2018-12-19
EP3294752A1 (en) 2018-03-21
JP2018520999A (ja) 2018-08-02
JP7372026B2 (ja) 2023-10-31
US10434134B2 (en) 2019-10-08
CA2984769C (en) 2023-03-21
WO2016182660A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
CN107531752B (zh) 用于炎症和纤维化的肽治疗
JP6676589B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
US20190023738A1 (en) Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
US20180344814A1 (en) Peptide therapeutics and methods for using same
US20160151446A1 (en) Peptide therapeutics and methods for using same
MX2014007799A (es) Peptidos y metodos para usarlos.
US20240108740A1 (en) Therapeutic compositions including spn10 and uses thereof
WO2017073764A1 (ja) 新規ｎｋ３受容体アゴニスト
ES2979305T3 (es) Composiciones y métodos para tratar enfermedades metabólicas
HK40076050A (en) Peptide treatment for inflammation and fibrosis
WO2016144352A2 (en) Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
JP2015514134A (ja) 芳香族カチオン性ペプチド及びその使用
KR102510514B1 (ko) 세포 살상제
WO2016190852A1 (en) Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
RU2820132C2 (ru) Способ улучшения симптомов со стороны нижних мочевыводящих путей
RU2825641C2 (ru) Способ повышения терапевтической эффективности фексапотида трифлутата при лечении снмп
RU2839726C2 (ru) Способ лечения симптомов со стороны нижних мочевыводящих путей с использованием фексапотида трифлутата
WO2012062953A1 (es) PÉPTIDO INHIBIDOR DE p38 Y APLICACIONES
US20240002441A1 (en) Peptides and uses thereof in modulation of amyloid-beta protein degrading proteases
US20180134763A1 (en) Brain penetrant amylin receptor based peptides for alzheimer's disease
WO2020000061A1 (en) Renal treatment
CN111163793A (zh) 血管紧张素受体激动剂及其用途
HK1178087A (en) Methods for performing a coronary artery bypass graft procedure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant